752 related articles for article (PubMed ID: 11429705)
1. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
2. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
5. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
[TBL] [Abstract][Full Text] [Related]
6. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
7. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
Kobayashi N; Takada Y; Hachiya M; Ando K; Nakajima N; Akashi M
Cytokine; 2000 Dec; 12(12):1745-54. PubMed ID: 11097743
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the molecular mechanisms for p53-mediated differentiation.
Chylicki K; Ehinger M; Svedberg H; Gullberg U
Cell Growth Differ; 2000 Nov; 11(11):561-71. PubMed ID: 11095245
[TBL] [Abstract][Full Text] [Related]
11. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
12. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells.
Gottlieb E; Lindner S; Oren M
Cell Growth Differ; 1996 Mar; 7(3):301-10. PubMed ID: 8838860
[TBL] [Abstract][Full Text] [Related]
13. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
14. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
15. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress.
Yin Y; Solomon G; Deng C; Barrett JC
Mol Carcinog; 1999 Jan; 24(1):15-24. PubMed ID: 10029406
[TBL] [Abstract][Full Text] [Related]
17. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
18. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
19. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
[TBL] [Abstract][Full Text] [Related]
20. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions.
Edwards SJ; Hananeia L; Eccles MR; Zhang YF; Braithwaite AW
Oncogene; 2003 Jul; 22(29):4517-23. PubMed ID: 12881708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]